Trial reportAlzheimer's & dementia : the journal of the Alzheimer's Association2012
Citalopram for agitation in Alzheimer's disease: design and methods.
Trial report in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00898807 (A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease), which is not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Antidepressants for treating depression in dementia.The Cochrane database of systematic reviews · 2018Pooled it
- Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial.Nature medicine · 2025Trial
- Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2021Trial
- Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease.American journal of Alzheimer's disease and other dementias · 2018Trial
- Structured physical exercise improves neuropsychiatric symptoms in acute dementia care: a hospital-based RCT.Alzheimer's research & therapy · 2017Trial
- Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.The American journal of psychiatry · 2016Trial
- Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.Journal of geriatric psychiatry and neurology · 2016Trial
- Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease.Journal of psychiatric research · 2016Trial
- Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.International psychogeriatrics · 2015Trial
- Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2015Trial
- Trial
- Depression and Suicidal Ideation During Two Psychosocial Treatments in Older Adults with Major Depression and Dementia.Journal of Alzheimer's disease : JAD · 2015Trial
- Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.JAMA · 2014Trial
- Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.PloS one · 2014Trial
- Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.The Journal of clinical psychiatry · 2013Trial
- Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET).The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2013Trial
- Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021Article
- What the COVID-19 pandemic entails for the management of patients with behavioral and psychological symptoms of dementia: experience in France.International psychogeriatrics · 2020Article
- Agitation and impulsivity in mid and late life as possible risk markers for incident dementia.Alzheimer's & dementia (New York, N. Y.) · 2020Review
- Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 9 institutions in 2 countries.
Funding
Abstract
backgroundAgitation is one of the most common neuropsychiatric symptoms of Alzheimer's disease (AD), and is associated with serious adverse consequences for patients and caregivers. Evidence-supported treatment options for agitation are limited. The citalopram for agitation in Alzheimer's disease (CitAD) study was designed to evaluate the potential of citalopram to ameliorate these symptoms.
methodsCitAD is a randomized, double-masked, placebo-controlled multicenter clinical trial, with two parallel treatment groups assigned in a 1:1 ratio and randomization stratified by clinical center. The study included eight recruiting clinical centers, a chair's office, and a coordinating center located in university settings in the United States and Canada. A total of 200 individuals having probable AD with clinically significant agitation and without major depression were recruited for this study. Patients were randomized to receive citalopram (target dose of 30 mg/d) or matching placebo. Caregivers of patients in both treatment groups received a structured psychosocial therapy. Agitation was compared between treatment groups using the NeuroBehavioral Rating Scale and the AD Cooperative Study- Clinical Global Impression of Change, which are the primary outcomes. Functional performance, cognition, caregiver distress, and rates of adverse and serious adverse events were also measured.
conclusionThe authors believe the design elements in CitAD are important features to be included in trials assessing the safety and efficacy of psychotropic medications for clinically significant agitation in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.